AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Phenethicillin potassium is effective against various bacterial infections, including streptococcal infections (such as strep throat), staphylococcal infections (including skin and soft tissue infections), and some respiratory tract infections caused by susceptible organisms.
Strep Throat: It is commonly used to treat streptococcal pharyngitis, also known as strep throat, which is caused by group A Streptococcus bacteria. Treatment helps alleviate symptoms and prevents complications like rheumatic fever or kidney inflammation.
Skin and Soft Tissue Infections: Phenethicillin potassium can be used to treat skin infections such as impetigo, cellulitis, and erysipelas, as well as soft tissue infections caused by susceptible bacteria.
Respiratory Tract Infections: In some cases, phenethicillin potassium may be prescribed for respiratory tract infections like sinusitis and bronchitis, particularly if they are caused by susceptible bacteria.
Prophylaxis: It may also be used prophylactically to prevent bacterial infections in certain situations, such as before dental procedures in individuals with a history of rheumatic fever or before surgical procedures to prevent postoperative infections.
Side Effects: Common side effects of phenethicillin potassium include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Allergic reactions, including skin rashes, itching, and, rarely, severe allergic reactions such as anaphylaxis, can occur. It may also cause superinfections due to overgrowth of non-susceptible organisms.
Drug Interactions: Phenethicillin potassium may interact with other medications, such as oral contraceptives, leading to decreased effectiveness of contraceptives. It is important to discuss all current medications with your healthcare provider before starting phenethicillin potassium.
Resistance: Like other antibiotics, the overuse or misuse of phenethicillin potassium can lead to the development of bacterial resistance, making future infections more difficult to treat. Therefore, it is essential to use antibiotics judiciously and only when necessary.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.9 | -0.04 |
| Allergies | 6.3 | 4.3 | 0.47 |
| Allergy to milk products | 2 | 1 | 1 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.9 | 7.6 | -0.1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.7 | 0.9 | 3.11 |
| Ankylosing spondylitis | 4.1 | 1.8 | 1.28 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1 | 0.3 | 2.33 |
| Asthma | 5.9 | 3.4 | 0.74 |
| Atherosclerosis | 2.1 | 2.4 | -0.14 |
| Atrial fibrillation | 4.1 | 2.5 | 0.64 |
| Autism | 11.2 | 10.7 | 0.05 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 2.4 | 2.4 | |
| Bipolar Disorder | 1.8 | 1.7 | 0.06 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.4 | 2.6 | 0.69 |
| Celiac Disease | 3 | 4.3 | -0.43 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 5.9 | 7.7 | -0.31 |
| Chronic Kidney Disease | 4.6 | 3.4 | 0.35 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 2 | 0.2 |
| Chronic Urticaria (Hives) | 0.8 | 1.8 | -1.25 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 2.5 | 1.6 | 0.56 |
| Colorectal Cancer | 7.7 | 2.2 | 2.5 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.8 | 3 | -0.67 |
| COVID-19 | 10.4 | 14.4 | -0.38 |
| Crohn's Disease | 9.2 | 6.9 | 0.33 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 2 | 1.4 | 0.43 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 12.7 | 11 | 0.15 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.6 | -0.53 |
| Endometriosis | 2.3 | 2 | 0.15 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.3 | 2.8 | 0.18 |
| erectile dysfunction | 0.8 | 0.3 | 1.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 5.7 | 4.9 | 0.16 |
| gallstone disease (gsd) | 3.1 | 1.6 | 0.94 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 2.7 | 2.5 | 0.08 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.6 | 1 | 1.6 |
| Graves' disease | 1.9 | 3 | -0.58 |
| Gulf War Syndrome | 0.9 | 2.1 | -1.33 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
| Heart Failure | 4.2 | 2.4 | 0.75 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 1.8 | 2.2 | -0.22 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.2 | 6.3 | -0.21 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 2.9 | 0.3 | 8.67 |
| IgA nephropathy (IgAN) | 1.9 | 5.1 | -1.68 |
| Inflammatory Bowel Disease | 9.7 | 11.4 | -0.18 |
| Insomnia | 2.5 | 3.5 | -0.4 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 8.3 | 6.4 | 0.3 |
| ischemic stroke | 2.6 | 1.1 | 1.36 |
| Liver Cirrhosis | 8 | 5.3 | 0.51 |
| Long COVID | 7.6 | 8.8 | -0.16 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1.6 | -0.78 |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1 | 2.4 | -1.4 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 8.2 | 9.6 | -0.17 |
| Mood Disorders | 13.3 | 8.9 | 0.49 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 8.4 | 7 | 0.2 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 1.6 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.3 | 5.9 | -0.11 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 11.7 | 10.6 | 0.1 |
| obsessive-compulsive disorder | 5.8 | 4.8 | 0.21 |
| Osteoarthritis | 2.7 | 1.7 | 0.59 |
| Osteoporosis | 1.9 | 1.9 | 0 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 9.4 | 7.7 | 0.22 |
| Polycystic ovary syndrome | 7.3 | 3.7 | 0.97 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 3.8 | 4 | -0.05 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9 | 4.7 | 0.91 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.8 | 3.6 | 1.17 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 2.6 | 3.2 | -0.23 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.6 | 1.67 |
| Stress / posttraumatic stress disorder | 3.1 | 3.3 | -0.06 |
| Systemic Lupus Erythematosus | 4.3 | 2.4 | 0.79 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 4.5 | 4.4 | 0.02 |
| Type 2 Diabetes | 9.1 | 7.9 | 0.15 |
| Ulcerative colitis | 5.8 | 8.4 | -0.45 |
| Unhealthy Ageing | 6.7 | 2.9 | 1.31 |
| Vitiligo | 2.5 | 2 | 0.25 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
